Cardiff Aims To Change Standard Of Care For Some Colorectal Cancers
Phase II data for onvansertib in first-line RAS-mutated metastatic colorectal cancer demonstrated impressive early efficacy and underpinned a $40m fundraising for the company.
Phase II data for onvansertib in first-line RAS-mutated metastatic colorectal cancer demonstrated impressive early efficacy and underpinned a $40m fundraising for the company.